Leqembi

Jul 24, 2026

Summary Alzheimer’s disease treatment has shifted from symptomatic management to disease modification with the emergence of anti-amyloid beta (Aβ) inhibitors that target the root cause by clearing amyloid plaques. Biogen/Eisai’s LEQEMBI and Eli Lilly’s KISUNLA are currently the only Aβ-targeting therapies to...

Feb 26, 2025

Alzheimer’s disease remains one of the most complex and devastating neurodegenerative disorders, affecting millions worldwide and placing an immense burden on patients, caregivers, and healthcare systems. Characterized by progressive cognitive decline, memory loss, and functional impairment, Alzheimer’s disease cur...

Feb 12, 2025

Alzheimer’s, the most common type of dementia, particularly with an increasing geriatric population, presents a major global crisis. The disease mostly occurs in sexagenarians, but it may manifest in quadragenarians. It is one of the most prevalent neurodegenerative disorders with a multifactorial pathogenesis. It ...

Feb 12, 2025

Alzheimer’s disease is the most common type of dementia, accounting for more than 60% of all cases, and is characterized by a gradual decline in cognitive and functional abilities. It represents a global health crisis that is increasing with the increasing geriatric population. It represents a global health crisis ...

Jul 08, 2024

The world of Alzheimer’s disease treatment witnessed a groundbreaking moment recently as the FDA approved Eli Lilly’s donanemab, marketed as KISUNLA. This new drug brings hope to millions of patients and their families struggling with this debilitating disease. Let us delve into the fascinating journey of donanemab...